@article{fdi:010075312,
  title = {{P}revalence of pretreatment {HIV} drug resistance in {W}est {A}frican and {S}outheast {A}sian countries},
  author = {{N}go-{G}iang-{H}uong, {N}icole and {H}uynh, {T}. {H}. {K}. and {D}agnra, {A}. {Y}. and {T}oni, {T}. {D}. and {M}aiga, {A}. {I}. and {K}ania, {D}. and {E}ymard-{D}uvernay, {S}abrina and {P}eeters, {M}artine and {S}oulie, {C}. and {P}eytavin, {G}. and {R}ekacewicz, {C}. and {C}haix, {M}. {L}. and {A}ghokeng {F}obang, {A}velin and {A}youba, {A}hidjo and {ANRS} {S}tudy {G}roup},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {ART} in the developing world has moved to a new era with the {WHO} recommendation to test and immediately treat {HIV}-positive individuals. {A} high frequency of pretreatment {HIV} drug resistance ({PDR}) can compromise {ART} efficacy. {O}ur study presents updated estimates of {PDR} in seven countries from {W}est {A}frica ({B}urkina {F}aso, {C}ameroon, {C}ate d'{I}voire, {M}ali and {T}ogo) and {S}outheast {A}sia ({T}hailand and {V}ietnam). {M}ethods: {E}ligible study participants were adult {ART} initiators, recruited from {D}ecember 2015 to {N}ovember 2016 in major {ART} clinics in each country. {HIV} drug resistance ({HIVDR}) tests were performed for all specimens and interpretation was done using the {S}tanford algorithm. {R}esults: {O}verall, 1153 participants were recruited and 1020 nt sequences were generated. {PDR} frequency among all initiators was 15.9% (95% {CI}: 13.8%-18.3%) overall, ranging from 9.6% and 10.2% in {B}urkina {F}aso and {T}hailand, respectively, 14.7% in {V}ietnam, 15.4% in {M}ali, 16.5% in {C}ote d'{I}voire and 19.3% in {C}ameroon, to 24.6% in {T}ogo. {T}he prevalence of {NNRTI} resistance mutations was 12%; {NRTI} and {PI} {PDR} prevalences were 4% and 3%, respectively. {C}onclusions: {O}ur study shows that in most countries {PDR} exceeded 10%, warranting the conduct of nationally representative surveys to confirm this trend. {I}n the meantime, actions to prevent drug resistance, including transition from {NNRTI}s to more robust drug classes should be urgently implemented.},
  keywords = {{BURKINA} {FASO} ; {CAMEROUN} ; {COTE} {D}'{IVOIRE} ; {MALI} ; {TOGO} ; {THAILANDE} ; {VIET} {NAM} ; {AFRIQUE} {DE} l'{OUEST} ; {ASIE} {DU} {SUD} {EST}},
  booktitle = {},
  journal = {{J}ournal of {A}ntimicrobial {C}hemotherapy},
  volume = {74},
  numero = {2},
  pages = {462--467},
  ISSN = {0305-7453},
  year = {2019},
  DOI = {10.1093/jac/dky443},
  URL = {https://www.documentation.ird.fr/hor/fdi:010075312},
}